Cargando…

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial

Invasive fungal disease (IFD) confers a substantial risk for morbidity and mortality to immunocompromised patients. Invasive aspergillosis (IA) is the most common IFD caused by moulds but the prevalence of other rare mould diseases, such as mucormycosis, hyalohyphomycosis and phaeohyphomycosis, may...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perfect, John R., Cornely, Oliver A., Heep, Markus, Ostrosky-Zeichner, Luis, Mullane, Kathleen M., Maher, Rochelle, Croos-Dabrera, Rodney, Lademacher, Christopher, Engelhardt, Marc, Chen, Caroline, Marty, Francisco M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490690/ https://www.ncbi.nlm.nih.gov/pubmed/29570857 http://dx.doi.org/10.1111/myc.12769

Ejemplares similares

824 An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis
por: Marty, Francisco M., et al.
Publicado: (2014)

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses
por: Thompson, George R., et al.
Publicado: (2016)

Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance
por: Ellsworth, Misti, et al.
Publicado: (2020)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

Post-exposure prophylaxis with isavuconazole after occupational exposure to Rhizopus
por: Al-Obaidi, Mohanad, et al.
Publicado: (2018)

Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole
por: Kovanda, Laura L., et al.
Publicado: (2017)

Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system
por: Schwartz, Stefan, et al.
Publicado: (2020)

1210 A Phase 3, Randomized, Double-Blind, Non-inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Neutropenic Patients
por: Patterson, Thomas, et al.
Publicado: (2014)

Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies
por: Hamed, Kamal, et al.
Publicado: (2023)

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016)

825 A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole vs Voriconazole in Patients with Invasive Mold Disease (IMD): Outcomes in Patients with Pulmonary Infections
por: Raad, Issam, et al.
Publicado: (2014)

Isavuconazole for invasive fungal infections
Publicado: (2020)

No Dose Adjustment for Isavuconazole Based on Age or Sex
por: Desai, Amit V., et al.
Publicado: (2019)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

Role of isavuconazole in the treatment of invasive fungal infections
por: Wilson, Dustin T, et al.
Publicado: (2016)

1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients
por: Arrieta, Antonio C, et al.
Publicado: (2023)

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
por: Jenks, Jeffrey D, et al.
Publicado: (2018)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature
por: Jacobs, Samantha E., et al.
Publicado: (2017)

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
por: Kovanda, Laura L., et al.
Publicado: (2016)

Prevention and Treatment of Yeast and Endemic Fungal Infections
por: Al Hammadi, Ahmed, et al.
Publicado: (2019)

Isavuconazole Treatment for Invasive Fungal Infections in Pediatric Patients
por: Zimmermann, Philippe, et al.
Publicado: (2022)

1726. Patterns of Isavuconazole Use for Invasive Fungal Infections
por: Gow-Lee, Vanessa, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
por: Harrington, Rachel, et al.
Publicado: (2016)

Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations
por: Natesan, Suganthini Krishnan, et al.
Publicado: (2016)

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization
por: Keirns, J, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Evaluation of the Drug‐Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2016)

Clinical research advances of isavuconazole in the treatment of invasive fungal diseases
por: Zhang, Tingting, et al.
Publicado: (2022)

819. Experience with Isavuconazole Use for Treatment of Invasive Fungal Infections
por: Gow-Lee, Vanessa, et al.
Publicado: (2023)

Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
por: Floros, Lefteris, et al.
Publicado: (2019)

Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis
por: Neofytos, Dionysios, et al.
Publicado: (2015)

Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations
por: Zurl, Christoph, et al.
Publicado: (2020)

Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections
por: Falci, Diego R, et al.
Publicado: (2013)

Experience of Isavuconazole as a Salvage Therapy in Chronic Pulmonary Fungal Disease
por: Nwankwo, Lisa, et al.
Publicado: (2022)

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
por: Kovanda, Laura L., et al.
Publicado: (2019)

1211 A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients
por: Kontoyiannis, Dimitrios, et al.
Publicado: (2014)

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
por: Koehler, Philipp, et al.
Publicado: (2021)

Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole
por: Bassetti, Matteo, et al.
Publicado: (2018)

Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease
por: Lee, Annie, et al.
Publicado: (2019)

Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support
por: Miller, Michelle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5fvdu7tbt88nnfhltdkll14ibo